COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines

Expert Rev Vaccines. 2020 Oct;19(10):937-947. doi: 10.1080/14760584.2020.1843432. Epub 2020 Nov 11.

Abstract

Introduction: The world is now facing the COVID-19 pandemic. Experience with SARS-CoV and MERS-CoV, and early reports about SARS-CoV-2 infection suggest that health-care settings and health-care workers (HCWs) are vulnerable in the context of the emergence of a new coronavirus. Areas covered: To highlight the need for prophylactic strategies particularly for HCWs, we identified SARS-CoV, MERS-CoV, and SARS-CoV-2 outbreaks in health-care settings and the incidence of infections in HCWs by a search on MEDLINE and MEDxRIV (for SARS-Cov-2). To identify prophylactic strategies against, we conducted a search on MEDLINE and clinicaltrials.gov about studies involving SARS-CoV, MERS-CoV, and SARS-CoV-2. Expert opinion: HCWs account for a great part of SARS, MERS, and SARS-CoV-2 infections, they may also contribute to the spread of the disease, particularly in health-care settings, and contribute to nosocomial outbreaks. Some preventive strategies were evaluated in previous emerging coronavirus epidemics, particularly in MERS-CoV. For COVID-19 prevention, different chemoprophylaxis with drug repositioning and new agents are under evaluation, and different vaccine candidates entered clinical development, with clinical trials. HCWs are a crucial target population for pre-exposure and post-exposure prophylaxis.

Keywords: Covid-19; MERS-CoV; SARS-CoV; healthcare personnel; healthcare workers; nosocomial transmission; outbreaks; post-exposure prophylaxis; pre-exposure prophylaxis; prevention; vaccines.

Publication types

  • Review

MeSH terms

  • COVID-19 / epidemiology
  • COVID-19 / prevention & control*
  • COVID-19 Drug Treatment
  • COVID-19 Vaccines / administration & dosage
  • Coronavirus Infections / epidemiology
  • Drug Development
  • Drug Repositioning
  • Health Personnel*
  • Humans
  • Infectious Disease Transmission, Patient-to-Professional / prevention & control*
  • Post-Exposure Prophylaxis
  • Severe Acute Respiratory Syndrome / epidemiology

Substances

  • COVID-19 Vaccines